This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00098892%3A_____%2F12%3A%230000333%21RIV13-MZ0-00098892/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00098892%3A_____%2F12%3A%230000333%21RIV13-MZ0-00098892
rdf:type
skos:Concept n13:Vysledek
dcterms:description
We assessed long-term outcome of 118 consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (IFN-α) in the Central and Northern Moravia region between 1989 and 2006 with focus on operational cure. The median follow-up was 82.6 months (range 12.4–212.6). Eighteen (15.3%) patients achieved complete cytogenetic response (CCyR) after median 16.7 (3.7–40.8) months. Nine of these patients (7.6%) achieved BCR-ABL negativity in nested reverse transcriptase–polymerase chain reaction [“complete” molecular response (CMR)] and 6 of them have been operationally cured without any treatment for median 6 (4–10) years, while 2 continue with IFN-α and 1 died from CML-unrelated cause. Operationally cured patients had a significantly lower percentage of initial peripheral promyelocytes, blasts, and erythroblasts than the rest of patients treated for more than 12 months (P=0.01–0.03). Unlike patients with sole CCyR, the majority of whom lost CCyR despite continuing IFN-α therapy and required imatinib, patients who achieved CMR had excellent long-term outcome We assessed long-term outcome of 118 consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (IFN-α) in the Central and Northern Moravia region between 1989 and 2006 with focus on operational cure. The median follow-up was 82.6 months (range 12.4–212.6). Eighteen (15.3%) patients achieved complete cytogenetic response (CCyR) after median 16.7 (3.7–40.8) months. Nine of these patients (7.6%) achieved BCR-ABL negativity in nested reverse transcriptase–polymerase chain reaction [“complete” molecular response (CMR)] and 6 of them have been operationally cured without any treatment for median 6 (4–10) years, while 2 continue with IFN-α and 1 died from CML-unrelated cause. Operationally cured patients had a significantly lower percentage of initial peripheral promyelocytes, blasts, and erythroblasts than the rest of patients treated for more than 12 months (P=0.01–0.03). Unlike patients with sole CCyR, the majority of whom lost CCyR despite continuing IFN-α therapy and required imatinib, patients who achieved CMR had excellent long-term outcome
dcterms:title
Operational cures after Interferon-apha in patients with chronic myeloid leukemia in Central and Northern Moravia Operational cures after Interferon-apha in patients with chronic myeloid leukemia in Central and Northern Moravia
skos:prefLabel
Operational cures after Interferon-apha in patients with chronic myeloid leukemia in Central and Northern Moravia Operational cures after Interferon-apha in patients with chronic myeloid leukemia in Central and Northern Moravia
skos:notation
RIV/00098892:_____/12:#0000333!RIV13-MZ0-00098892
n13:predkladatel
n14:ico%3A00098892
n3:aktivita
n5:I
n3:aktivity
I
n3:cisloPeriodika
5
n3:dodaniDat
n7:2013
n3:domaciTvurceVysledku
n8:3547159
n3:druhVysledku
n6:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
156680
n3:idVysledku
RIV/00098892:_____/12:#0000333
n3:jazykVysledku
n15:eng
n3:klicovaSlova
interferon-alpha, chronic myeloid leukemia, operational cure
n3:klicoveSlovo
n9:operational%20cure n9:interferon-alpha n9:chronic%20myeloid%20leukemia
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[C53CF4271355]
n3:nazevZdroje
Journal of Interferon & Cytokine Research
n3:obor
n16:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
9
n3:rokUplatneniVysledku
n7:2012
n3:svazekPeriodika
32
n3:tvurceVysledku
Kuba, Adam Faber, Edgar
s:issn
1079-9907
s:numberOfPages
5